Literature DB >> 16896062

Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol.

Hiroshi Yamazaki1, Makiko Shimizu, Takashi Nagashima, Masaki Minoshima, Norie Murayama.   

Abstract

Propofol (2,6-diisopropylphenol) is a widely-used anesthetic agent attributable to its rapid biotransformation. Liver microsomal cytochrome P450 (P450) isoforms involved in the biotransformation of propofol in rats and the effects of propofol in vivo on P450 levels in rats were investigated. Of six cDNA-expressed rat P450 isoforms tested, CYP2B1 and CYP2C11 had high catalytic activities from 5 microM and 20 microM propofol concentrations, respectively. Rates of propofol metabolism, at a substrate concentration of 20 microM based on the reported human blood concentration, were decreased by intraperitoneal treatment of propofol with male rats, in contrast to a strong induction by phenobarbital. Single intravenously administered propofol (10 mg/kg) caused the decrease of total P450 and CYP2C contents and activities of testosterone 16alpha-hydroxylation and propofol metabolism in liver microsomes from male rats. The suppressive effects were caused by administered propofol (10 mg/kg) twice every 4 h on CYP2B activities such as testosterone 16beta-hydroxylation or pentoxyresorufin O-depentylation, in addition to the strong suppression of CYP2C function by the single propofol treatment. These results suggest that CYP2C11, presumably deactivated by propofol, has an important role in propofol metabolism in rat liver microsomes. Repeated administration of propofol could markedly decrease the biotransformation of propofol via P450 deactivation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896062     DOI: 10.1124/dmd.106.011627

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling.

Authors:  Hiroshi Yamazaki; Kana Horiuchi; Ryohji Takano; Taku Nagano; Makiko Shimizu; Masato Kitajima; Norie Murayama; Fumiaki Shono
Journal:  Int J Environ Res Public Health       Date:  2010-09-01       Impact factor: 3.390

2.  Ring-oxidative biotransformation and drug interactions of propofol in the livers of rats.

Authors:  Yu-Ting Tai; Yi-Ling Lin; Chia-Chen Chang; Yih-Giun Cherng; Ming-Jaw Don; Ruei-Ming Chen
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

3.  An unexpected increase of entropy in a sleepwalking disorder patient during propofol and remifentanil anesthesia: a case report.

Authors:  Yoon Ji Choi; Koo Kwon; Go Eun Bae; Seung Zhoo Yoon; Hye Won Lee; Hae Ja Lim
Journal:  Korean J Anesthesiol       Date:  2014-10-27

4.  Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation.

Authors:  Radek Indra; Petr Pompach; Václav Martínek; Paulína Takácsová; Katarína Vavrová; Zbyněk Heger; Vojtěch Adam; Tomáš Eckschlager; Kateřina Kopečková; Volker Manfred Arlt; Marie Stiborová
Journal:  Int J Mol Sci       Date:  2019-07-10       Impact factor: 5.923

5.  A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and Their Contributions to This Reaction in Human and Rat Livers: Experimental and Theoretical Approaches.

Authors:  Marie Stiborová; František Bárta; Kateřina Levová; Petr Hodek; Heinz H Schmeiser; Volker M Arlt; Václav Martínek
Journal:  Int J Mol Sci       Date:  2015-11-18       Impact factor: 5.923

6.  Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo.

Authors:  Helena Dračínská; František Bárta; Kateřina Levová; Alena Hudecová; Michaela Moserová; Heinz H Schmeiser; Klaus Kopka; Eva Frei; Volker M Arlt; Marie Stiborová
Journal:  Toxicology       Date:  2016-02-01       Impact factor: 4.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.